Conference abstractPublished 20 Mar 2019
Development of the unique diagnostic platform for HER2-positive breast cancer patient (Hybrid sensor and actuator system for cancer diagnostics)
Oncompass Medicine Hungary Ltd., Hungary MTA-SE Pathobiochemistry Research Group, Hungary
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Breast cancer is the most frequent cancer among women and responsible for approximately 15% of all their cancer deaths. Approximately 20% of patients with early-stage HER2-positive breast cancer can benefit from Herceptin (trastuzumab) therapy which was approved by FDA in 2006. Therefore, an early diagnosis of biomarkers is a critical factor in breast cancer therapy. The Oncompass Medicine Hungary Ltd., as a member of the ADMONT â?? â??Advanced Distributed Pilot Line for More-than-Moore Technologiesâ?� project aimed to develop a novel diagnostic platform for detection of HER2-positive circulating tumor cells (CTCs) from blood next to the patientâ??s bed. The platform design based on the lab-on-chip solution is supported by MtM (More-than-Moore) technology. LED-based photodetectors observes the colorimetric response of CTCs with different level of HER2 expression. Commercially available CTC isolation method was optimised to improve CTC yield from blood-based cellular model system and patient derived material. An alkaline phosphatase-based (AP) detection system was set on blood-based cellular breast cancer model system to assess the sensitivity of the detector arrays and meet the characteristics of the prototype device. Our developments introduce a unique integrated diagnostic system that is faster, costeffective and requires less number of cells or sample material than conventional techniques such as flow cytometry (FACS), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). As a novel molecular diagnostic system for personalized medicine, it enables detection of HER2-expression to select patients for cancer therapy and also screening of therapy response, based on a less-invasive and easily repeatable sampling. The research leading to these results has received funding from NEMZ_15-1-2016-0002 project.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Anna Sipos”
- BylineArticles whose byline prints “Zsuzsanna Poka-Farkas”
- BylineArticles whose byline prints “Pal Gyulavari”
- BylineArticles whose byline prints “Edit Zdravicsne Szabo”
- BylineArticles whose byline prints “Edit Varkondi”
- BylineArticles whose byline prints “Istvan Petak”
